Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2− advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 tria...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer Res Treat
Main Authors: O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2017
Fag:
Clinical Trial
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847028/
https://ncbi.nlm.nih.gov/pubmed/29164421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4518-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker